Delivering Compounded Medications: The Logistics Obligations Most Pharmacies Underestimate
Compounding pharmacies occupy a position in the South African healthcare system that is at once highly specialised and surprisingly underregulated in practice. The preparation itself is governed by SAHPRA guidelines and the South African Pharmacy Council’s good pharmacy practice standards. The pharmacist who compounds is accountable. The facility in which compounding occurs is inspected. And then the preparation leaves the pharmacy. What happens next, in most compounding pharmacy operations, is managed with considerably less formal attention than what preceded it.
The courier who collects the medication may or may not understand its temperature requirements. The vehicle in which it travels may or may not be capable of maintaining those requirements. The documentation that arrives with the delivery may or may not constitute an adequate record of the conditions the preparation experienced between the dispensary and the patient or facility that receives it. For a product prepared with exacting attention to formulation, sterility, and potency, this is a striking inconsistency with consequences that most compounding pharmacies have not formally examined.
What Makes Compounded Preparations Different
Compounded preparations are not manufactured pharmaceuticals. They are patient specific or patient group specific preparations, made in response to a prescription or a standing order, in quantities and formulations that are not commercially available or not commercially suitable for the individual patient’s needs. The categories are broad. Hormone replacement preparations in strengths or delivery forms not available commercially. Paediatric preparations in concentrations appropriate for small children. Wound care preparations combining multiple active ingredients at specified concentrations. Sterile preparations including injectable medications, ophthalmic solutions, and intravenous admixtures prepared in a cleanroom environment under aseptic conditions.
Each of these categories has specific stability characteristics, storage requirements, and handling sensitivities defined by the formulation itself rather than by a manufacturer’s product monograph. The compounding pharmacist knows these characteristics because they determined the formulation. The courier does not know them unless the pharmacy makes a deliberate effort to communicate them. In most compounding pharmacy logistics arrangements, that communication does not happen systematically.
The Stability Question That Logistics Arrangements Rarely Address
Every compounded preparation has a beyond use date, assigned by the pharmacist based on the stability data available for the formulation, the container type, and the storage conditions under which the preparation will be held. The beyond use date assumes that the preparation is stored correctly from the moment it leaves the compounding environment. It does not account for the conditions the preparation experiences in transit. For temperature sensitive preparations, this distinction matters considerably. A compounded progesterone cream assigned a beyond use date of 30 days when stored at room temperature has been assigned that date on the assumption that room temperature means a controlled ambient environment of approximately 15 to 25 degrees Celsius. A cream that spent two hours in a courier vehicle at 38 degrees Celsius in Johannesburg’s January heat before being delivered to the patient has not been stored at room temperature for its entire shelf life.
The same logic applies to compounded preparations requiring refrigeration. A hormone replacement gel requiring storage at 2 to 8 degrees Celsius that was transported in an unmonitored insulated bag with a partially depleted gel pack may have experienced a temperature excursion during transit that shortened its effective stability period below the beyond use date indicated on the label. The patient using that preparation on day 20 of a 30 day supply is using a preparation whose potency and stability may have been compromised before it reached them. These consequences are almost never detected, because the patient experiencing subtherapeutic effect from a compounded preparation does not connect that experience to a delivery event that occurred weeks earlier.
Sterile Preparations and the Non-Negotiable Transport Standard
For sterile compounded preparations, the stakes are higher still. Sterile compounded medications include injectable preparations, ophthalmic solutions, intravenous admixtures, and intrathecal or epidural preparations. These products are prepared under aseptic conditions in a cleanroom environment specifically to eliminate microbial contamination. Their sterility is an absolute requirement, not a quality preference. A sterile preparation that is contaminated is not merely a suboptimal product. It is a potentially dangerous one.
The integrity of sterile preparations during transport depends on the integrity of their primary container closure system. A glass vial with a properly seated rubber stopper, crimp sealed with an aluminium cap, is a robust barrier against microbial ingress under normal handling conditions. That barrier can be compromised by physical shock, excessive vibration, improper orientation during transport, and temperature extremes that affect the dimensional integrity of the closure system. A compounding pharmacy that prepares sterile medications to a high standard of aseptic technique and then dispatches them with a general courier in an unmonitored bag has created a quality gap between the standard of preparation and the standard of distribution that is inconsistent and indefensible from a quality assurance perspective.
Patient Specific Delivery and the Documentation Obligation
Compounded preparations are patient specific. Each preparation is made for a named patient, against a
valid prescription, in a quantity appropriate for the prescribed course. The documentation chain that
supports a compounded preparation begins with the prescription and ends with evidence of receipt by the
patient or their carer. In a medico-legal context, that chain matters. If a patient claims harm from a compounded preparation, the pharmacy’s defence depends on its ability to demonstrate that the preparation was correctly formulated, correctly labelled, correctly stored, and correctly delivered to the correct recipient. If the delivery record consists only of a general courier’s confirmation that a package was delivered to an address, and the patient denies receiving it or denies that it arrived in good condition, the pharmacy has no evidence to offer.
A delivery record that includes a timestamped delivery, the identity of the person who received the preparation, a temperature log for the transit period where the preparation had cold chain requirements, and confirmation that it was delivered to the correct recipient provides a documentary foundation that a general courier delivery confirmation cannot. For compounding pharmacies servicing institutional clients including hospitals, clinics, and specialist practices, the documentation requirement extends further. Institutional recipients may require batch records, preparation records, and chain of custody documentation as part of their own quality management obligations.
The Scope of Temperature Requirements Across Compounding Categories
The range of temperature requirements across different compounding categories is broader than a single logistics arrangement can accommodate without deliberate design. Room temperature preparations require protection from heat extremes during transport but do not require active refrigeration. In Johannesburg’s summer, ambient temperatures in unventilated vehicles can reach 50 degrees Celsius. A preparation assigned a room temperature storage requirement and transported in a vehicle cab during a delivery run in January may experience conditions well outside its stability range without anyone being aware.
Refrigerated preparations require active cold chain management during transport. Frozen preparations require frozen transport with dry ice or validated frozen shipping systems. Building a logistics model that accommodates all three temperature categories, with documented handover and temperature records for each, requires a courier partner who has the equipment, the training, and the systems to differentiate between them rather than treating all compounded preparations as equivalent cargo.
The Regulatory Expectation That Most Compounding Pharmacies Are Not Meeting
SAHPRA’s guidelines for pharmacy compounding and the South African Pharmacy Council’s good pharmacy practice standards place the quality obligation for a compounded preparation on the pharmacist responsible for its preparation and dispensing. That obligation does not end when the preparation leaves the dispensary. The distribution of a compounded pharmaceutical product is part of the quality chain for which the pharmacist carries professional responsibility. Appointing a logistics provider that cannot demonstrate the capability to maintain the preparation within its storage requirements during transit, cannot produce a temperature record for the delivery, and cannot provide a chain of custody record is not consistent with that responsibility.
Most compounding pharmacies in South Africa have not examined their delivery arrangements against this
standard, because the regulatory attention has historically been directed at the preparation environment
rather than the distribution chain. That attention is shifting, as it has shifted in analogous regulatory contexts internationally. Compounding pharmacies that have not brought their logistics arrangements into alignment with the same standard they apply to their preparation processes are carrying an exposure that is likely to become more visible as regulatory scrutiny of the full compounding quality chain increases.
